Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zifivax Booster After CoronaVac in Adults
NCT05205096Phase 2Completed
- Sponsor
- Zhifei Biological
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ZF2001 in coronavirus disease 2019 (COVID-19), sponsored by Zhifei Biological. Primary endpoint: Immunogenicity endpoint (Neutralizing antibody detection) at 14 days. Started Nov 2021; status: completed.
02
Drugs
ZF2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05205096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205096.